Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fingolimod (0.5 Mg)

Bekanntmachung

Construction Of Drainage Systems

Evaluation funding KiFöG MV 220-174-KH-23

Open House Discount Contracts 2023-13

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Golimumab (Atc Code According to Who: L04ab06)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Natalizumab (Exclusively in the Dafo Infusion Solution Concentrate), Atc L04aa23 for the Period December 1St, 2023-Novembe...

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Golimumab (Atc Code According to Who: L04ab06)

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Infliximab (Atc Code According to Who: L04ab02), which is Used Subcutaneously. Applicants are Approved

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Infliximab (Atc Code According to Who: L04ab02), which is Used Subcutaneously. Applicants are Approved